Genetic Targeting of Metastatic Pancreatic Cancer Using CRISPR-Cas9
Author Information
Author(s): Bowland Kirsten, Lai Jiaying, Skaist Alyza, Zhang Yan, Teh Selina Shiqing K., Roberts Nicholas J., Thompson Elizabeth, Wheelan Sarah J., Hruban Ralph H., Karchin Rachel, Bailey Matthew H., Iacobuzio-Donahue Christine A., Eshleman James R.
Primary Institution: The Johns Hopkins University School of Medicine
Hypothesis
Can metastatic cancer be genetically targeted by exploiting unique mutations that occur during normal aging?
Conclusion
The study found that regions of genetic instability in pancreatic adenocarcinomas are retained in metastases, suggesting potential targets for CRISPR-based gene therapy.
Supporting Evidence
- 90% of PAM targets were maintained between primary carcinomas and metastases.
- Regions of truncal LOH are strongly retained in the presence of genetic instability.
- CRISPR-Cas9 targeting of these regions may provide a novel approach to treat metastatic cancer.
Takeaway
The researchers looked at how certain genetic changes in pancreatic cancer are kept the same in tumors that spread, which could help create new treatments.
Methodology
Whole genome sequencing was performed on five rapid autopsy cases of patient-matched primary tumor, normal and metastatic tissue.
Potential Biases
Potential bias from using cell lines that may not fully capture the genetic diversity of the original tumors.
Limitations
The study relied on cell lines for sequencing, which may not represent all cases of cancer due to low cellularity in primary tumors.
Participant Demographics
80% male and 20% female participants were included in the study.
Statistical Information
P-Value
0.0011
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website